Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.

Ahmed Hamed Salem; Jianning Yang; Alison Graham; Amita Patnaik; Kyle Holen; Rajendra Pradhan; Hao Xiong

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.

【24h】

Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.

机译：酮康唑共同施用强大的CYP3A抑制剂，对Navitoclax的药代动力学，安全性和耐受性，癌症患者癌症患者的一流的口服BCL-2家族抑制剂。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Co-administration of navitoclax with ketoconazole did not increase navitoclax exposure above that observed with navitoclax monotherapy and did not appear to affect its safety profile. Results suggest CYP3A does not play a major role in elimination of navitoclax.

机译：Navitoclax与酮康唑的共同施用并未增加与Navitoclax单疗法观察到的Navitoclax暴露，并且似乎没有影响其安全性。结果表明CYP3A在消除Navitoclax时不会发挥重要作用。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2014年第4期|共6页
作者
Ahmed Hamed Salem; Jianning Yang; Alison Graham; Amita Patnaik; Kyle Holen; Rajendra Pradhan; Hao Xiong;
展开▼
作者单位

Clinical Pharmacology and Pharmacometrics AbbVie Inc;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. [J] . Ahmed Hamed Salem, Jianning Yang, Alison Graham, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：酮康唑共同施用强大的CYP3A抑制剂，对Navitoclax的药代动力学，安全性和耐受性，癌症患者癌症患者的一流的口服BCL-2家族抑制剂。
2. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. [J] . Ahmed Hamed Salem, Jianning Yang, Alison Graham, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：酮康唑（一种强CYP3A抑制剂）的共同给药对癌症患者中一流的口服Bcl-2家族抑制剂navitoclax的药代动力学，安全性和耐受性的影响。
3. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer [J] . YangJ., PradhanR.S., RosenL.S., Journal of Clinical Pharmacy and Therapeutics . 2014,第6期

机译：利福平对Bcl-2和Bcl-XL双重抑制剂navitoclax（ABT-263）的药代动力学，安全性和耐受性的影响
4. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptofic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity [C] . Can-Hui Zheng, Jia-Guo Lv, Ju Zhu, International conference of molecular simulations and applied informatics technologies . 2012

机译：抗凋亡Bcl-2家族蛋白的广谱小分子抑制剂的设计，合成和活性评估：广谱蛋白结合的特征及其对抗肿瘤活性的影响
5. Evaluating novel chemotherapeutic strategies in colorectal and gastric cancer: The role of histone deacetylase inhibitors and human epidermal receptor family inhibitors. [D] . LaBonte, Melissa J. 2010

机译：在结直肠癌和胃癌中评估新型化疗策略：组蛋白脱乙酰基酶抑制剂和人类表皮受体家族抑制剂的作用。
6. Effect of ketoconazole a strong CYP3A inhibitor on the pharmacokinetics of venetoclax a BCL‐2 inhibitor in patients with non‐Hodgkin lymphoma [O] . Suresh K. Agarwal, Ahmed Hamed Salem, Alexey V. Danilov, 2017

机译：酮康唑（一种强CYP3A抑制剂）对非霍奇金淋巴瘤患者Venetoclax（一种BCL-2抑制剂）的药代动力学的影响
7. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity [O] . Wyndham H Wilson, Owen A OConnor, Myron S Czuczman, 2010

机译：Navitoclax，Bcl-2的靶向高亲和力抑制剂，淋巴恶恶性肿瘤：安全，药代动力学，药效学和抗肿瘤活性的1阶段剂量升级研究

Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.

摘要

著录项

相似文献

相关主题

期刊订阅